P-TEFb inhibitors interfere with activation of p53 by DNA-damaging agents (Q80854497)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17724473%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

title

P-TEFb inhibitors interfere with activation of p53 by DNA-damaging agents (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17724473%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

author

Senthil K Radhakrishnan

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17724473%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

author name string

Bhat UG

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17724473%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Halasi M

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17724473%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Gartel AL

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17724473%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

publication date

3 September 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17724473%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17724473%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

volume

27

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17724473%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17724473%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

page(s)

1306-1309

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17724473%20AND%20SRC:MED&resulttype=core&format=json

Regulation of p53 function and stability by phosphorylation

4 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210737

7 January 2021

Phase 1 trial of flavopiridol combined with cisplatin or carboplatin in patients with advanced malignancies with the assessment of pharmacokinetic and pharmacodynamic end points.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210737

7 January 2021

Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210737

7 January 2021

Disruption of p53 in human cancer cells alters the responses to therapeutic agents

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210737

7 January 2021

Flavopiridol induces p53 via initial inhibition of Mdm2 and p21 and, independently of p53, sensitizes apoptosis-reluctant cells to tumor necrosis factor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210737

7 January 2021

Resistance of p53 knockout cells to doxorubicin is related to reduced formation of DNA strand breaks rather than impaired apoptotic signaling

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210737

7 January 2021

Gene-specific requirement for P-TEFb activity and RNA polymerase II phosphorylation within the p53 transcriptional program

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210737

7 January 2021

p21(WAF1/CIP1) response to genotoxic agents in wild-type TP53 expressing breast primary tumours

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210737

7 January 2021

DNA-dependent protein kinase and checkpoint kinase 2 synergistically activate a latent population of p53 upon DNA damage

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210737

7 January 2021

Identification of a chemical inhibitor of the oncogenic transcription factor forkhead box M1.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210737

7 January 2021

Constitutive expression of E2F-1 leads to p21-dependent cell cycle arrest in S phase of the cell cycle

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210737

7 January 2021

CDK9 phosphorylates p53 on serine residues 33, 315 and 392

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210737

7 January 2021

A novel transcriptional inhibitor induces apoptosis in tumor cells and exhibits antiangiogenic activity.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210737

7 January 2021

Phosphorylation of p53 on key serines is dispensable for transcriptional activation and apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210737

7 January 2021

Surfing the p53 network

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210737

7 January 2021

The ins and outs of p53

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210737

7 January 2021

Doxorubicin induces apoptosis in normal and tumor cells via distinctly different mechanisms. intermediacy of H(2)O(2)- and p53-dependent pathways

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210737

7 January 2021

Increased and altered DNA binding of human p53 by S and G2/M but not Gl cyclin-dependent kinases

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210737

7 January 2021

DNA-dependent protein kinase acts upstream of p53 in response to DNA damage

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210737

7 January 2021